NCT01017263

Vyvanse and Glucose Intolerance in Children With Attention Deficit Hyperactivity Disorder (ADHD) and Obesity

Vyvanse and Glucose Intolerance in Children With ADHD and Obesity

• Status: Terminated
• Phase: Phase 4
• Study type: Interventional
• Enrollment: 14 (actual)
• Sponsor: Duke University · Academic / Other
• Sex: All
• Age: 8 Years – 17 Years
• Healthy volunteers: Accepted

Summary

The purpose of this study to assess the effects of chronic administration of Vyvanse (lis-dexamphetamine) on glucose metabolism in a sample of children and adolescents with Attention Deficit Hyperactivity Disorder (ADHD) who also have glucose intolerance and are obese.

Conditions

• Attention Deficit Hyperactivity Disorder
• Glucose Intolerance
• Obesity

Interventions

Type	Name	Description
DRUG	Lis-dexamphetamine	Eligible subjects will be dispensed open label LDX (VyvanseTM). All subjects will start at 20 mg once a day dose and will be titrated up weekly by 10 mg increments up to a maximum dose of 70 mg. If a subject experiences intolerable side effects at a particular dose, a step down to the next tolerated level is allowed.

Timeline

• Start date: 2009-12-01
• Primary completion: 2012-08-01
• Completion: 2012-08-01
• First posted: 2009-11-20
• Last updated: 2014-02-20
• Results posted: 2014-02-20

Locations

1 site across 1 country: United States